Alternative translation initiation augments the human mitochondrial proteome

Lawrence Kazak*, Aurelio Reyes*, Anna L. Duncan, Joanna Rorbach, Stuart R. Wood, Gloria Brea-Calvo, Payam A. Gammage, Alan J. Robinson, Michal Minczuk and Ian J. Holt*

MRC-Mitochondrial Biology Unit, Wellcome Trust-MRC Building, Cambridge CB2 0XY, UK

Received September 3, 2012; Revised December 2, 2012; Accepted December 3, 2012

ABSTRACT

Alternative translation initiation (ATI) is a mechanism of producing multiple proteins from a single transcript, which in some cases regulates trafficking of proteins to different cellular compartments, including mitochondria. Application of a genome-wide computational screen predicts a cryptic mitochondrial targeting signal for 126 proteins in mouse and man that is revealed when an AUG codon located downstream from the canonical initiator methionine codon is used as a translation start site, which we term downstream ATI (dATI). Experimental evidence in support of dATI is provided by immunoblotting of endogenous truncated proteins enriched in mitochondrial cell fractions or of co-localization with mitochondria using immunocytochemistry. More detailed cellular localization studies establish mitochondrial targeting of a member of the cytosolic poly(A) binding protein family, PABPC5, and of the RNA/DNA helicase PIF1α. The mitochondrial isoform of PABPC5 co-immunoprecipitates with the mitochondrial poly(A) polymerase, and is markedly reduced in abundance when mitochondrial DNA and RNA are depleted, suggesting it plays a role in RNA metabolism in the organelle. Like PABPC5 and PIF1α, most of the candidates identified by the screen are not currently annotated as mitochondrial proteins, and so dATI expands the human mitochondrial proteome.

INTRODUCTION

Products of nuclear genes dominate the mitochondrial proteome. They are synthesized by cytosolic ribosomes and imported into mitochondria via specific pathways according to their final destination in the organelle (1). The most extensively used system for importing matrix-destined mitochondrial proteins depends on a positively charged amphipathic α helix, located at the amino (N+) terminus of the protein, which functions as a mitochondrial targeting signal (MTS). Cytosolic proteins chaperone mitochondrial precursors to an import complex located on the outer surface of the mitochondrion, termed the translocase of the outer membrane (TOM) complex. The MTS can interact with import receptors and direct proteins across both the outer and inner mitochondrial membranes. Matrix-destined proteins depend additionally on the translocase of the inner membrane (TIM) complex, specifically TIM23, to direct them to the innermost compartment of the organelle. The insertion of proteins into the TIM23 channel requires a membrane potential across the inner mitochondrial membrane, and a further driving force is provided by the presequence translocaase-associated motor complex. Upon entry to the matrix, many proteins have the MTS removed by the mitochondrial processing peptidase, and chaperones facilitate the proper folding of the mature protein into its active conformation (1,2). Although many genes encode dedicated mitochondrial proteins, an increasing number are recognised to specify multiple protein isoforms that are found in more than one cellular compartment. Protein variants that are targeted to different cellular compartments can be synthesized from a single gene, or transcript, via the use of alternative splice sites, transcription start sites or translation initiation sites (3). Alternative translation initiation (ATI), first discovered in viruses (4,5), and subsequently in eukaryotes (6), is a mechanism by which more than one initiation codon within a single mRNA results in the translation of proteins with distinct N-termini (3,7). ATI diversifies the proteome and may alter a protein’s function or cellular location.

The use of an MTS lends itself to ATI, as essentially the same mature protein can be made for two compartments from one gene. RNase H1 is typical of this class of genes (8). Other documented examples of ATI-dependent...
Our studies of nucleic acid-transacting proteins in mitochondria led us to the finding that dATI yields a mitochondrial isoform of flp endonuclease 1, FEN1 (manuscript in preparation). Taken together with the previous instance of dATI-mediated mitochondrial targeting of the thyroid hormone receptor, the possibility arose that this might be a commonplace mechanism of mitochondrial targeting. Therefore, using a computational approach, an inventory comprising 126 genes encoding candidate dATI-dependent mitochondrial isoforms was assembled. Experimental validation of a subset of the putative genes from the list provided empirical evidence of mitochondrial localization, indicating that mitochondrial targeting via dATI is much more widespread than recognized hitherto.

MATERIALS AND METHODS

Cell culture and transfections

Human 143B osteosarcoma (HOS) cells were maintained in DMEM supplemented with 0.1% penicillin/streptomycin and 10% FBS. Flp-In™ T-REx™ 293 (HEK293T) cells (Invitrogen) were cultured in DMEM, 0.1% penicillin/streptomycin, 10% tetracycline-free FBS, 15 μg/ml Blasticidin (InvivoGen) and 100 μg/ml Zeocin (Invivogen). HEK293T cells were co-transfected, using Lipofectamine 2000 (Invitrogen), with 1350 ng pOG44 (Invivogen). HEK293T cells were grown on glass coverslips and transiently transfected using Lipofectamine 2000 with 1.5 μg of Pif1, Pabpc5 and Pop1 cDNAs. Twenty-four hours after transfection, HOS cells were incubated with anti-HA antibodies, followed by treatment with appropriate fluorescently labelled secondary antibodies. Coverslips were mounted with 1,4-diazabicyclo[2.2.2]octane (Sigma), containing 4,6-diamidino-2-phenylindole (DAPI). Images were acquired with an LSM 510 META confocal microscope (Carl Zeiss, Jena, Germany).
Samples were centrifuged at 100 000g for 1 h at 4°C. The supernatants were retained as the matrix fractions, whereas pellets comprised mitochondrial membrane proteins.

**Immunoprecipitation**

Mitochondria were isolated from PABPC53.HA-, PABPC53.F-, or PDE12.F-overexpressing HEK293T cells and treated with proteinase K (PK) (0.02 mg/5 mg mitochondrial) for 30 min on ice. PK was inactivated with PMSF and then mitochondria were lysed in lysis buffer (50 mM Tris–HCl, pH 7.4; 150 mM NaCl, 1 mM EDTA, 1% triton X-100). Debris was removed by centrifugation at 8000g max, and supernatant was incubated with E-Zview Red Anti-HA affinity gel (Sigma) or anti-FLAG M2 affinity gel (Sigma) for 1 h at 4°C. Beads were washed three times in wash buffer (50 mM Tris–HCl, pH 7.4; 150 mM NaCl). In the case of HA immunoprecipitation, beads were boiled, centrifuged and supernatant was used for immunoblotting. In the case of FLAG co-immunoprecipitation experiments, proteins were eluted from beads using 3X FLAG peptide (Sigma).

**Iodixanol density gradients**

Purified mitochondria were treated with 100 μg/ml trypsin for 30 min at room temperature, washed, lysed with 0.4% dodecyl maltoside (DDM) and loaded on to a 20–42.5% iodixanol density gradient (Sigma) and ultracentrifuged at 100 000g for 14 h at 4°C.

**Mitochondrial DNA analysis**

Mitochondrial DNA was extracted and analysed via Southern blotting as previously described (14).

**In silico analysis for generating the dATI inventory**

Protein sequences from the human and mouse genomes were downloaded from the ensembl genome browser, release 61 (15). Human–mouse orthology data were obtained from the ensembl genome browser via BioMart (www.ensembl.org/biomart.martview). For all protein sequences, each methionine occurring in the first quarter of the sequence was queried for possible dATI, with mitochondrial targeting predicted using Mitoprot (16), TargetP (17) and iPSORT (18). Genes were considered mitochondrial when they encoded at least one protein, which, when encoded from an alternative translation site, satisfied two of the following three criteria: (i) Mitoprot score >0.95; (ii) TargetP score >0.95 and (iii) positive iPSORT result. Retaining only those genes considered mitochondrial for both their human and mouse orthologs further filtered the inventory. Finally, the genes whose protein products were predicted to localize to mitochondria if their translation would start at M1 were removed from the inventory. Genes whose protein products that started at M1 were considered mitochondrial when they satisfied two of the following three criteria: (i) Mitoprot score >0.5; (ii) TargetP score >0.5 and (iii) positive iPSORT result.

**RESULTS**

A genome-wide screen identifies 126 candidate dATI-dependent mitochondrial proteins

As a test of the idea that many proteins achieve mitochondrial targeting via downstream alternative translation initiation (dATI), every in-frame AUG codon within the first quarter of all annotated human and mouse protein-coding genes of the ensembl database was assessed as a potential translation initiation site. The choice to restrict the analysis to the first quarter of the longest annotated protein isoform was made to reduce the probability of identifying gene products that were truncated at the N-terminus to such an extent that functional domains within the open reading frame (ORF) were lost. Putative mitochondrial targeting was evaluated based on predictions from Mitoprot (16), TargetP (17) and iPSORT (18). Two of three conditions were required: a Mitoprot score >0.95, a TargetP score >0.95 and a positive iPSORT result. These criteria were established with the aim of minimizing false positives; however, this risked failing to identify genuine mitochondrial proteins that depend on dATI for targeting to the organelle.

When the computational analysis was applied, 886 entries (473 and 413, human and mouse genes, respectively) scored above the threshold set (Figure 1A). Human and mouse data sets were combined and only orthologous genes were retained, yielding 168 candidates. Forty-two of these were excluded (Supplementary Table S1) because the full-length protein has a plausible N-terminal MTS (an MTS starting at M1), and approximately half of these are found in the Mitocarta database (19). This suggests that these proteins can achieve mitochondrial targeting without the need for dATI. Thus, the final catalogue (Supplementary Table S2) comprised 126 genes that potentially depend on dATI to generate a mitochondrially targeted protein.

**Antibody- and immunocytochemistry-based identification of dATI candidates**

Of the 126 genes identified by the in silico screen (Supplementary Table S2), five are recognized mitochondrial proteins in the Mitocarta database (19), and 17 others can be found in the MitoMiner database (20). Thus, the computational screen identified >100 proteins that have had no prior evidence of mitochondrial localization. This might be taken to imply that the screen generated many false positives. However it is noteworthy that the established dATI-dependent mitochondrial protein, e-Erb A z1, is missing from the Mitocarta and Mitominer databases. As an initial test of the validity of the dATI screen, the cellular distribution of 26 proteins with no prior localization to mitochondria was analysed. Fifteen proteins predicted by the in silico screen to have a cryptic MTS, and 11 negative controls, were studied in enriched nuclear, cytosolic and mitochondrial preparations, by immunoblotting or by immunocytochemistry. The proteins were selected without bias, while aiming to reflect a range of biological processes. For immunoblotting analyses, the prediction, a priori, was that the
antibody would cross-react with a protein that was (i) enriched in mitochondrial extracts, (ii) shorter than the annotated full-length protein, while being maximally of a size predicted by dATI and (iii) resistant to trypsin degradation prior to mitochondrial lysis, like other internal mitochondrial proteins. For immunocytochemistry analysis, two versions of the cDNA were cloned, the full-length ORF, and a truncated form starting at the internal AUG predicted to mark the start of the cryptic MTS. In the immunoblotting experiments, 10 of 15 proteins tested fulfilled the criteria, suggesting they have a mitochondrial isoform. The 10 positive proteins were
ARAP1, FBXL12, MTSS1L, LEPRE1, TRIM32, NOX3, CLASP2 and FOXH1 (Figure 1B), as well as PABPC5 and PIF1α (see below). In the case of FBXL12, the MT5 may not always be cleaved after import, as the antibody to this protein detected two bands specific to the mitochondrial cell fraction (Figure 1B).

There was no putative mitochondrial isoform in the cases of TNIK, PRPSAP2, MBRL or NRF1 (Supplementary Figure S1A). POP1 was another false positive, based on immunocytochemistry of the full-length and putative dATI isoform, as both long and short forms of the protein were targeted exclusively to nucleoli (Supplementary Figure S2). None of the negative controls tested yielded a short, trypsin-resistant, mitochondrial isoform based on immunoblotting (Supplementary Figure S1B). Therefore, our screen achieved a sensitivity and specificity of 77 and 72% respectively, with an estimated false discovery rate (FDR) of 33%. These results suggest that ~85 of the 126 identified genes will prove to encode dATI-dependent mitochondrial proteins, and thus are strong candidates for further validation. Nevertheless, multiple methods will be required to demonstrate that each predicted dATI-dependent gene product is a bona fide mitochondrial protein. On the other hand, a dATI variant that is predicted to be mitochondrial, but not detected in the organelle at first instance, should not be discounted, as dATI might be tightly regulated in some cases, and so the mitochondrial isoform might only be apparent in specific cell types, environmental conditions or stages of development.

The predicted polyA-binding protein PABPC5 has a dATI-dependent mitochondrial isoform

Poly(A) tails are attached to the 3'-end of almost all eukaryotic messenger RNAs, including those in mitochondria (21,22), and polyA-binding proteins (PABPs) bind to and modulate polyA tail length, with implications for mRNA stability and translation (22). Hence, mitochondria are expected to contain one or more PABPs, yet none had been identified hitherto. Therefore, the appearance of PABPC5 in the list of candidate proteins (Supplementary Table S2) was of particular interest, as it could be the long sought mitochondrial PABP (23).

Initiation from an internal AUG codon of Pabpc5 occurs in vitro, and human mitochondria contain a truncated isoform of PABPC5 concordant with dATI

The computational analysis predicted that translation initiation from methionine 33 of PABPC5 would generate a mitochondrial isoform of the protein. To test this prediction, Pabpc5 cDNAs were introduced into a coupled transcription/translation (TnT) system. Full-length Pabpc5 cDNA (PABPC5) produced two polypeptides (Figure 2A; lane 2) corresponding to translation products initiating at M1 and M33, based on comparisons with an N-terminally truncated template (PABPC5M33) (Figure 2A; lane 1), whereas a full-length mutant form of the protein, where M33 was replaced by isoleucine (PABPC5M33I) (Figure 2A; lane 3), yielded a single polypeptide. Thus, the downstream AUG at position 33 is a functional start site.

An antibody to PABPC5 detected two proteins in the cytosol of HEK293T cells, the lower of which was also detected in trypsin-treated mitochondria (Figure 2B). Sub-mitochondrial fractionation localized the protein to the matrix compartment of the organelle (Supplementary Figure S3A), and in vitro synthesized PABPC5 resolved at the same position as the endogenous mitochondrial isoform of PABPC5 on SDS-PAGE gels (Figure 2C). In addition, full-length PABPC5 tagged at the carboxyl-terminus (PABPC5.HA) was targeted principally to the cytosol based on immunocytochemistry (Figure 2D), whereas deletion of the first 32 residues (PABPC533.HA) resulted in targeting of the protein to mitochondria, as predicted by the in silico screen (Figure 2E). Next, mitochondria were purified from transgenic HEK293T cells expressing FLAG-tagged PABPC5, starting at M33 (PABPC533.F), or full-length PABPC5 with a methionine-to-isoleucine mutation at the predicted internal start site (PABPC5M33.F). The full-length mutant protein was readily detectable in whole cell extracts, and as expected for a cytosolic protein, the little associated with isolated mitochondria was completely degraded with the addition of trypsin (Figure 2F). In contrast, tagged PABPC533 co-purifying with mitochondria survived trypsin treatment (Figure 2F). Therefore, translation initiation from methionine 33 of Pabpc5 yields a protein that is targeted to mitochondria in living cells.

Mitochondrial PABPC5 co-fractionates with mtDNA to a similar extent as DNA polymerase γ and mitochondrial single-stranded DNA-binding protein

To determine whether PABPC5 in mitochondria associated with nucleic acid, mitochondrial lysates were subfractionated through an iodixanol gradient. Southern blotting was used to detect mtDNA, and the co-fractionation of PABPC5 and known mtDNA replication proteins was assessed by immunoblotting. The majority of the signal from proteins known to be involved in mtDNA metabolism, such as TWINKLE, TFAM, SSBP1 and POLG1, resolved in the same fractions as mtDNA, whereas the chaperone protein HSP60 was mainly in the mtDNA-free fractions (Figure 3A). PABPC5 showed a distribution similar to SSBP1 and POLG1 (Figure 3A), suggesting that it is associated with mtDNA or RNA, as mitochondrial ribosomes and mRNAs co-fractionate with the DNA on iodixanol gradients (24).

Depletion of mtDNA destabilizes mitochondrial PABPC5

Many proteins associated with mitochondrial nucleic acid are rapidly turned over in its absence (25). To test whether mitochondrial PABPC5 was dependent on nucleic acid for its stability, HEK293T cells were largely depleted of their mitochondrial DNA and RNA by treatment with ethidium bromide (26,27). In these conditions, mitochondrial PABPC5 was markedly reduced in abundance, as were several known mtDNA and RNA-binding proteins, such as SLIRP, LRPPRC, DHX30, PTCD3, POLRMT.
Figure 2. PABPC5 has a mitochondrial isoform consistent with dATI from M33. (A) SDS-PAGE of [35S]-methionine-labelled PABPC5 polypeptide variants generated in vitro. M33 and M1 denote the methionines where translation starts, while M33I indicates a methionine to isoleucine point mutation at residue 33 of PABPC5. A consensus Kozak sequence (gccacc) was placed upstream of the first AUG (methionine) codon in each construct. Schematics of the constructs used as templates are indicated to the right of the representative gel image. 'X' in the cDNA schematic (lane 3) indicates mutation of the methionine residue. (B) Immunoblot analysis of PABPC5 cytosolic (Cytos), and mitochondrial fractions from HEK293T cells. Mitochondrial fractions were treated with 0, 10 or 50 μg/ml trypsin. Gray arrowhead, full-length protein; white arrowhead, putative dATI isoform. (C) Immunoblot analysis using anti-PABPC5 to PABPC533 and PABPC5M33I TnT products, total mitochondrial lysate (TM) and a mitochondrial matrix fraction (Mtrx). Confocal analysis of transiently transfected HOS cells with C-terminal HA-tagged cDNAs encoding (D) full-length human PABPC5 (PABPC5.HA) or (E) the dATI isoform with the first methionine at residue 33 (PABPC533.HA). Recombinant proteins were labelled with anti-HA antibody (green), while nuclei (blue) and mitochondria (red) were visualized by staining cells with DAPI and Mitotracker, respectively. (F) Mitochondria from PABPC5M33I-F- and PABPC533.F-expressing cells (10 ng/ml doxycycline, 24 h) were purified
and TFAM, whereas the mitochondrial protein Aconitase II, which does not interact with mtDNA, was unaffected by this treatment (Figure 3B). These results suggest that PABPC5 interacts with nucleic acid in mitochondria.

PABPC5 co-immunoprecipitates the mitochondrial poly(A) polymerase, but not mitochondrial ribosomes

Co-immunoprecipitation experiments, followed by immunoblotting, were used to determine potential protein-protein interactions, using the predicted dATI isoform of PABPC5, fused to a carboxy-terminal haemagglutinin (HA) or FLAG tag, as bait. Tagged PABPC533 co-immunoprecipitated the mitochondrial poly(A) polymerase (mtPAP), and to a lesser extent LRPPRC, whereas a FLAG-tagged version of the mitochondrial deadenylase, PDE12 (28), did not interact with either of these proteins (Figure 3C and Supplementary Figure S3B). There was no enrichment of the mitochondrial RNA-binding protein SLIRP, nor was there any significant co-immunoprecipitation of the mitochondrial ribosomal protein, MRPS18, or the abundant respiratory chain subunit cytochrome c oxidase (COXIV) (Figure 3C and Supplementary Figure S3B). The specific interaction of PABPC533 with mtPAP and LRPPRC, but not MRPS18, suggests it associates with mRNAs that are independent of mitochondrial ribosomes.

The RNA/DNA helicase PIF1 has a dATI-dependent mitochondrial isoform

Another dATI candidate from the in silico screen was the RNA/DNA helicase PIF1. In yeasts, the PIF1 gene product is essential for mitochondrial DNA maintenance (29), and the mitochondrial isoforms of budding and fission yeast PIF1 are known to be generated via ATI, not dATI. Translation initiation from the first AUG codon of the ORF yields the mitochondrial isoform, whereas translation from a downstream in-frame AUG codon generates yeast nuclear PIF1 (30,31). In contrast, none of the annotated PIF1 transcripts in a variety of vertebrates possesses an in-frame AUG that could append an MTS to the protein (Supplementary Table S3). Nor do these PIF1 orthologs contain a proximal recognition motif.

The predicted dATI forms of human and mouse PIF1 are targeted to mitochondria in cultured cells, and mutation of an internal AUG codon ablates mitochondrial localization of PIF1

PIF1 was shown to display nuclear localization based on an N-terminal FLAG-tagged (FLAG.PIF1) form of the protein (32,33). However, dATI bypasses N-terminal tags; therefore, cDNAs specifying full-length PIF1 tagged with HA, either at the N-terminus (HA.PIF11) or the C-terminus (PIF11.1.HA), were transiently expressed in

Figure 2. Continued

and subjected to trypsin protection assays, followed by immunoblotting. Schematic representations of the transgenes are depicted above the immunoblots. M1, indicates translation initiation at the annotated start methionine of PABPC5 according to ensembl genome browser, release 61; M33, indicates the band corresponding to the cDNA product starting from the dATI residue of PABPC5. Whole cell extract (WCE, lanes 1 and 7); black slope, indicates increasing trypsin concentrations (μg/ml) of 0 (lanes 2 and 8); 10 (lanes 3 and 9); 50 (lanes 4 and 10); and 100 μg/ml (lanes 5 and 11). L, mitochondria lysed with 1% Triton X-100 and treated with 100 μg/ml trypsin, lanes 6 and 12. PABPC5-F transgenes were detected with anti-FLAG antibody. Heat shock protein 60 (HSP60), mitochondrial marker; GAPDH, cytosolic marker. TOM20 was used to show efficiency of trypsin treatment. Full-length and predicted dATI protein products of candidate genes are schematically depicted to the right. RRM1, RNA recognition motif.
human cells. HA.PIF1α, like FLAG.PIF1α, was located exclusively in the nucleus (Figure 5A), whereas the products of the C-terminally tagged, full-length PIF1α cDNA (PIF1αH.A) co-localized chiefly with mitochondria, with a small amount of signal detected in nuclei (Figure 5B). Enforced translation from M54 (PIF1αM54.HA) resulted in exclusive mitochondrial targeting of the protein (Figure 5C), whereas replacing M54 with isoleucine (I54) yielded a protein that did not co-localize with mitochondria (Figure 5D). These results show that a functional MTS is revealed when human PIF1α starts at M54, and that this residue is required to generate a mitochondrial isoform of PIF1α. Analysis of mouse PIF1 constructs provided further support for the generation of a mitochondrial-targeted form of PIF1 via dATI, as mPIF167.HA (the mouse equivalent of PIF1αM54.HA) co-localized with mitochondria (Figure 5E), whereas there was no detectable PIF1 in mitochondria after mutating the AUG codon predicted to yield translation initiation of the mitochondrial isoform of mouse PIF1 (mPIF1M671.HA) (Figure 5F).

N-terminally truncated human PIF1α is imported and processed by mitochondria in cultured cells

Subcellular fractions were prepared from human cells expressing PIF1αH.A, PIF1αM54.HA or PIF1αM54.HA to determine the location of the recombinant proteins. Tagged full-length PIF1α (M1) was the only signal detected in purified nuclei (Figure 6A, lane 1), and although some of this isoform was also associated with mitochondrial fractions (Figure 6A, lane 2), it was degraded by trypsin treatment (Figure 6B, lanes 3–5). The mitochondrial extracts additionally contained two shorter PIF1α products, one corresponding to the pre-protein (M54) and the other to a shorter protein (m) (Figure 6A, lane 2). We infer that the shorter of the two is the mature form of mitochondrial PIF1α, both because it is the more abundant and it is similar in size (the small difference being attributable to the tag) to an endogenous mitochondrial protein identified by the PIF1 antibody (Figures 3A and 4E). Consistent with this interpretation, cells expressing PIF1αM54.HA produced only the two presumed mitochondrial-specific species, M54 and m, both of which were resistant to degradation by trypsin (Figure 6C). Thus, full-length PIF1α is outside mitochondria, whereas M54 and m are located inside the organelle. Both these mitochondrial isoforms depend on

---

**Figure 3.**Continued

---
Figure 4. Mammalian PIF1 has a predicted dATI-dependent mitochondrial isoform, some of which can be imported into isolated mitochondria. (A) N-terminal amino acid sequence alignment of PIF1 between human, orangutan, mouse, pig, cow, dolphin and megabat. M1 and M54 above the alignment correspond to methionines 1 and 54, respectively of human PIF1α. Green font and box, canonical start sites in mouse and human; red font and box, putative methionine residue where dATI begins; blue font, Mitoprot-predicted cleavable MTS. (B) In silico mitochondrial targeting prediction scores from: Mitoprot, TargetP, Predotar (35), PSORTII (36) and iPSORT of human and mouse PIF1. ‘M’ followed by a number, on the left side of the heat map, indicate the methionine residue numbers; red-coloured boxes in the heat map indicate strong prediction for
Figure 4. Continued

mitochondrial targeting. (C) SDS-PAGE of [35S]-methionine-labelled human PIF1α polypeptide variants generated in vitro. M54 and M1 refer to the methionines where translation starts, while M54I indicates a methionine to isoleucine point mutation at residue 54 of PIF1α. A consensus Kozak sequence (gccacc) was placed upstream of the first AUG (methionine) codon in each construct. Schematics of the constructs used as templates are indicated to the right of the gel image. ‘X’ in the cDNA schematic (lane 3) indicates mutation of the methionine residue. (D) [35S]-methionine-labelled TFAM (positive control), PIF1α and PIF1α54 were incubated with isolated rat liver mitochondria. 1 μM FCCP (lanes 5–7) was used to dissipate membrane potential. White arrowheads indicate imported polypeptide. Import efficiency was determined relative to import of TFAM. Start methionines are indicated to the right of the gel images. (E) HEK293T cells were transfected with 200 pmol of scrambled siRNA (siCON) or siRNA targeted towards PIF1 (siPIF1). Forty-eight hours later, whole cell extracts were used for immunoblotting with anti-PIF1. GAPDH was used as a loading control. The chart accompanying the immunoblots shows the extent of knockdown relative to GAPDH protein (n = 3 independent experiments).

Figure 5. Immunocytochemistry of ectopically expressed human and mouse PIF1 suggests mitochondrial targeting via dATI. HOS cells were transiently transfected with human Pif1α full-length cDNA containing a HA tag on either the (A) N-terminus (HA.PIF1α1) or (B) C-terminus (PIF1α1.HA). The remaining Pif1α constructs were HA-tagged on the C-terminus, consisting of Pif1α.HA cDNAs that were (C) forced to start at M54 (PIF1α54.HA) or (D) with a methionine to isoleucine substitution at residue 54 (PIF1αM54I.HA). Mouse PIF1 (mPIF1) constructs were C-terminally tagged and included (E) a cDNA forced to start translation at M67 (mPIF167.HA) or (F) a cDNA encoding a methionine-to-isoleucine mutation at residue 67 (mPIF1M67I.HA). Recombinant proteins were labelled with anti-HA antibody (green), nuclei were stained blue with DAPI, and mitochondria were stained red with Mitotracker.
TFAM and SF2 are mitochondrial and nuclear markers, respectively. TOM20 was used to show efficiency of trypsin treatment. (B and D) A species (cPIF1α) migrating between M54 and m was detected in cells expressing PIF1α\(^{54}\).HA variant, and all derivatives of PIF1α\(^{54}\).HA were degraded when mitochondria were exposed to trypsin (Figure 6D).

A species (cPIF1α) migrating between M54 and m was detected in cells expressing PIF1α\(^{1}\).HA (Figure 6B, lane 1), and this was the major product in PIF1α\(^{54}\).HA cells (Figure 6D, lanes 1 and 2). In the latter cells, the recombinant protein was dispersed throughout the cytosol (Figure 5D), and cPIF1α did not survive trypsin treatment of intact mitochondria (Figure 6B and D). Thus, cPIF1α probably represents a proteolytic cleavage product that is formed after export of tagged PIF1α from the nucleus, as occurs to the native protein during the course of the cell cycle (32). In contrast, murine PIF1\(^{M6\beta}\).HA was concentrated in the nucleus (Figure 5F), and so it may not be recognized by the human nuclear export machinery. Similarly, the HA N-terminal tag may interfere with nuclear export of PIF1α\(^{1}\) (Figure 5A). In summary, dATI from the AUG corresponding to M54 of human PIF1α generates a pre-protein, PIF1α\(^{54}\), which is cleaved after mitochondrial import, yielding a mature mitochondrial isoform, PIF1α\(^{m}\), and mutation of the predicted dATI sites ablates mitochondrial isoforms of human and mouse PIF1.

**Endogenous N-terminally truncated PIF1α is present in mitochondria and co-fractionates with mtDNA**

The mitochondrial lysates fractionated by iodixanol gradient sedimentation and probed for PABPC5 were also used to evaluate endogenous forms of PIF1. The most abundant form of PIF1 detected by immunoblotting corresponded to PIF1α\(^{m}\) (the presumed mature dATI isoform of PIF1α), 30% of which co-fractionated with mtDNA (Figure 3A). The largest species detected by the PIF1 antibody was a polypeptide of \(~75\) kDa, which is the predicted size of PIF1β (33), and it was concentrated in the same fractions as the mtDNA. Thus, there appear to be two forms of PIF1 in human mitochondria, PIF1α\(^{m}\) and PIF1β, both of which may interact with mtDNA.

**DISCUSSION**

The mammalian mitochondrial proteome is estimated at 1500 proteins. If accurate, then some 400 mitochondrial proteins remain to be identified (19). The dATI-generated mitochondrial proteins predicted from our analysis could account for a substantial fraction of the ‘missing’ mitochondrial proteome, as \(>100\) gene products in our list have not previously been annotated as mitochondrial proteins. Ten of 15 candidates tested from the 126-gene inventory appear to have a form of the protein in mitochondria corresponding to the predicted dATI isoform. Taking account of the estimated false discovery rate of 33%, then \(~85\) of the identified genes may prove to yield proteins targeted to mitochondria in a dATI-dependent manner. However, in view of the low specificities of mitochondrial prediction programs, it is inevitable that many genes will be missing from the inventory. The thyroid hormone receptor c-Erb A \(\alpha 1\) (11) is a known example. Thus, the number of proteins targeted to mitochondria via dATI could be in the hundreds. Although the dATI screen could be refined further to include the likes of c-Erb A \(\alpha 1\), simply lowering the threshold for acceptance will inevitably produce a marked increase in false positives. This might be offset in other
ways, such as a greater demand for conservation among diverse species, or the incorporation of additional algorithms that predict mitochondrial targeting (37). Conservation is a critical filter because randomly generated peptides can create an MTS (38). As noted above, evidence of mitochondrial involvement will be an important guide in many cases and this is likely to be facilitated by the explosion in RNA expression data providing comprehensive details of co-expression in a variety of cell and tissue types. Detailed mining of existing and new mitochondrial proteome studies will also doubtless reap reward, as it is likely that many mitochondrial proteins have been mistakenly dismissed as contaminants, β-actin being a case in point (14). Conversely, it is possible that some genes on the list have genuine mitochondrial isoforms that do not depend on a canonical N-terminal MTS, or are generated via alternative transcripts, rather than by dATI. Ultimately any in silico prediction of putative internal start codons will require experimental verification by multiple methods for each and every candidate, as per PIF1 and PABPC5.

Although the known or inferred functions of the 126 candidate mitochondrial dATI proteins are highly varied, they can be grouped into a number of categories (Table 1). Thirty-one of the candidates have links to RNA or DNA metabolism, and these can be further sub-divided into transcriptional regulation, post-transcriptional modification and DNA replication or repair. The earlier identification of nuclear transcription factors in mitochondria led others to suggest that the regulation of mitochondrial gene expression might share certain aspects with nuclear gene expression (39), and 17 candidate dATI-generated mitochondrial proteins are recognized transcriptional regulators (Table 1). Actomyosin has recently been found inside mammalian mitochondria and implicated in mtDNA maintenance (14), and 12 candidates have links to actin binding and organization, two of which were substantiated by immunoblotting (Figure 1B). Furthermore, the list includes two members of the WNK (WNK lysine-deficient protein kinase) serine/threonine kinase subfamily (WNK1 and WNK2), which act on Rho GTPases and control actin dynamics. These two proteins physically interact with one another (40), and WNK1 enhances the activity of the annotated mitochondrial protein, SGK1 (serum- and glucocorticoid-induced kinase 1) (41). Thus, dATI may be a mechanism of protein trafficking that maintains the balance between mitochondrial and cytoplasmic actin.

dATI-dependent mitochondrial isoforms confound conventional genetic analysis, as gene knockdown and ablation will affect all the protein isoforms, and so the relative contributions of the mitochondrial and non-mitochondrial proteins cannot be judged. Gene replacement of one particular isoform could circumvent this problem, as was achieved for the alternatively translated DNA ligase III, which identified the mitochondrial, not the nuclear, enzyme as the essential variant for cell viability (42).

Based on the immunoblotting results and the domain structure of some of the dATI candidates (Figure 1B), loss of a portion of the N-terminus will affect their function. For instance, the dATI isoform of FBXL12 is predicted to lack the F-box-like domain that gives it its name (Figure 1B), and half of a RNA recognition motif is missing from the mitochondrial isoform of PABPC5 (Figure 2F).

The dATI-mediated mitochondrial isoform of PABPC5

Although several mitochondrial proteins have been shown previously to bind RNA and poly(A) sequences in mitochondria (43–45), none binds poly(A) tails preferentially. Of the four human PABPC genes, three (PABPC1, PABPC3 and PABPC4) are established polyA-binding proteins (46–48); however, none has a predicted N-terminal MTS based on the annotated first AUG codon, or downstream AUG codon, and only PABPC5 predicts a dATI-dependent mitochondrial isoform. Several lines of evidence provide support for the proposed dATI-mediated mitochondrial isoform of PABPC5. A cDNA of the complete ORF yields two proteins, one of which is of the size predicted by dATI, and when expressed in cells the shorter form is imported into mitochondria. Endogenous PABPC5 is present in mitochondria (PABPC5m) based on immunoblotting, and it co-fractionates with mitochondrial nucleic acids. PABPC5m is unstable when mitochondrial DNA and RNA are depleted, and it interacts with mitochondrial RNA-binding proteins, implying PABPC5m in mitochondria is bound to RNA. Hence, PABPC5m is proposed to play a role in post-transcriptional mitochondrial RNA metabolism, and based on its high homology to other PABP family members, it is a highly credible candidate for the long sought mitochondrial poly(A)-binding protein. All four PABPCs contain four non-identical RNA recognition motifs (RRMs). Typically, these motifs are linked to a C-terminal domain through a proline-rich (P-rich) region (22). However, the C-terminus of PABPC1 can be deleted without affecting poly(A) binding in vitro (49), or compromising translation in Xenopus (50) or viability in yeast (51). Only RRM motifs 1 and 2 need be retained to preserve the protein’s ability to bind to poly(A) tails (52). Moreover, whereas RRMs 1 and 2 are highly selective for polyadenylated RNA, RRMs 3 and 4 are less discriminating, and can also bind AU-rich RNA (48), and this may be an important feature of the mitochondrial variant of PABPC5, as some mitochondrial transcripts have been shown to be polyuridinylated, poly(U) (53,54). Therefore, although full-length PABPC5 lacks the P-rich linker region and the C-terminal domain of the other PABPCs (55), and the dATI form lacks RRM1 (Figure 2F), both cytosolic and mitochondrial isoforms of PABPC5 are still likely to have the capacity to bind to polyadenylated RNA. Nevertheless, the structural differences between PABPC5 and the other family members might be indicative of a distinct property or role, and the function of the shorter mitochondrial isoform may differ from its cytosolic counterpart.

The dATI mediated mitochondrial isoform of PIF1α

In the case of PIF1α, dATI exposes the MTS and simultaneously removes the nuclear localization signal (NLS).
Prior research on PIF1 assigned it a nuclear location, based chiefly on N-terminal tagging of the recombinant protein (32,33). However, N-terminal tags mask mitochondrial targeting signals that are present at the N-terminus (24), and a protein derived from an internal MTS will be undetectable because dATI bypasses N-terminal tags. Therefore, the previous approach was not capable of revealing a mitochondrial isoform of PIF1. Accordingly, C-terminal tags are most appropriate for localization studies of potential mitochondrial proteins.

Based on its mobility on denaturing gels, the mass of the dATI-dependent mitochondrial PIF1 (PIF1m) is estimated at 55 ± 2.5 kDa, placing the cleavage site at residue 165 ± 30. Despite PIF1m being processed to an even shorter form upon mitochondrial import, to generate PIF1m, the mature form is not expected to differ substantially from the full-length protein in terms of its core activities, because the first defined functional SFI helicase motif begins at residue 224 (56), which PIF1m appears to retain. Furthermore, a recombinant form of human PIF1 (PIF1ΔN) lacking the first 166 residues

Table 1. Functional categories of candidate dATI genes

| Transcriptional regulation | Post-transcriptional modification | DNA Replication/Repair | Actin cytoskeleton | Kinases | Translation |
|---------------------------|----------------------------------|-----------------------|-------------------|--------|-------------|
| ASH2L                      | C19orf6                          | C9orf102              | ANK2              | MINK1  | RPL4        |
| C1orf30                    | DHX15                            | TEP1                  | ANK3              | MAP4K4 | FTSJ3       |
| PHTF1                      | ER1                              | PIF1                  | ARAP1             | MLKL   | DUS4L       |
| SMARC81                    | PAPPC5                           | ZNF335                | FARP2             | PRKCE  | E1F2S1      |
| TRRAP                      | POP1                             | ZRANB3                | IQSEC1            | TNIK   | RPS15       |
| ZMYM3                      | RBM25                            |                       | IQSEC2            |        |
| ZMYM4                      | SRRM2                            |                       | MTSS1             | WNK1   | BMS1        |
| ELK4                       | NFKB1L1                          |                       | MTSSIL            | WNK4   |             |
| FOXH1                      | YTHDC2                           |                       | MYO10             |        |
| GATA4                      |                                  |                       | MYO15A            |        |
| MLF1                       |                                  |                       | STARD13           |        |
| NR112                      |                                  |                       | ARHGAP32          |        |
| NKF1                       |                                  |                       |                   |        |
| PAN4                       |                                  |                       |                   |        |
| MYST3                      |                                  |                       |                   |        |
| NR6A1                      |                                  |                       |                   |        |
| SRFBP1                     |                                  |                       |                   |        |

Collagen: COL16A1, COL27A1, LEPRE1
Microtubules: CLASP2, SF1, ASPM
Beta oxidation: CPT1B, CPT1C
Receptors: CHRM1, CHRM5
GTP binding: C9orf86, RASAL3
Calcium sensing: MCTP1, IQCF5
Channels: ACCN1, SCNN1A, TRPM2, CACNA1B, CACNA1F, HCN1, TMC6, CYBB
Traficking: NUP155, YIPF3, DOPEY1, CLINT1, CCDC157, HCN1, NC1, NMFCT
Ubiquitination: FBXL12, RNF111, TRIM2, ZYG11B, FBXO38, COMMD10, C1QTNF3
Cell–cell communication: DSP, DTX4, ICA1, PKP4, SRCN1, C1QTNF3
Proteases: MMP25, MMP28, PSMD1, RHDPL3, TMPPRSS11F, CTSF, AGBL1, USP49
Transporters: MCTP1, IQCF5
Apoptosis: SPATA17, PNPLA6, IDH1, NOX3, NOX4
Phospho-lipase: PRPSAP2
Cysteine modification: HHAT, CYP26A1
Retinoic acid metabolism: PISD
Phospholipid biosynthesis: PLCB4
Unknown function: FAM160B1, C1orf118

All 126 genes from Supplementary Table S2 were grouped according to known function. Bold font, genes tested in this study, that have a product in mitochondria based on experiment, unless coloured gray; blue font, genes found in human Mitocarta; red font, genes found in Mitominer.
has the same ATPase and helicase activities as the full-length protein (57). Therefore, the activities of PIF1\(\alpha\) are expected to be similar to its full-length nuclear counterpart, although contextual differences between nuclei and mitochondria might mean that the function of PIF1\(\alpha\) is distinct from the long form of PIF1\(\alpha\), in vivo.

**Human PIF1\(\beta\)—the alternatively spliced mitochondrial isoform**

The detection, with an antibody to PIF1, of a protein of a mass of \(\sim 75\) kDa co-fractionating with mtDNA (Figure 3A), lends support to the proposal that alternative splicing gives rise to a dedicated transcript encoding a human mitochondrial PIF1 isoform, PIF1\(\beta\) (33). PIF1\(\beta\) is annotated as a manually verified transcript in the ensemble database. Assuming it is correctly assigned, PIF1\(\beta\) starts at M1 and so depends on signals located at the C-term (which PIF1\(\alpha\) lacks) to achieve mitochondrial targeting (33). However, a genetic approach that targets PIF1\(\beta\), while sparing PIF1\(\alpha\) will be needed to clarify its physiological importance, as PIF1\(\beta\) does not appear to be conserved even among primates (Supplementary Figure S4). Orangutan lacks the consensus splice acceptor site, which in humans gives rise to PIF1\(\beta\) mRNA, and in mouse there are no annotated alternative mouse PIF1 isoforms. Although there is a putative AG splice acceptor site in the mouse Pif1 gene, the resultant four-nucleotide insertion directly downstream would create a variant PIF1 unlike human PIF1\(\beta\) (Supplementary Figure S4). Moreover, this hypothetical mouse PIF1 mRNA does not contain any appreciable homology (at the nucleotide level) to the portion of the human PIF1\(\beta\) protein that is required for mitochondrial targeting (33). Therefore, there is no evidence of a PIF1\(\beta\) mouse variant. Nevertheless, there is considerable sequence variation among mitochondrial targeting signals and so it remains possible that the mouse PIF1 sequence contains a carboxy-terminal MTS.

**The extent of dATI-dependent mitochondrial targeting**

An increasing number of nuclear DNA transacting proteins are also found in mitochondria (33,58–60), but the task of defining the organelle-specific forms is far from complete. Information regarding the subcellular localization of these proteins is essential for determining their precise roles within the cell. The identification of dATI-dependent mitochondrial isoforms of PABPC5 and PIF1\(\alpha\) suggests that this trafficking mechanism will prove to be a significant contributor to the dual targeting of proteins. Other candidates well worthy of further investigation for a role in mitochondrial nucleic acid metabolism include the putative RNA exonuclease ER13 and the RNA helicase YTHDC2 (Table 1 and Supplementary Table S2).

*In silico* screen and cell biology data of this report strongly support the idea of dATI playing an important role in targeting proteins to mitochondria, potentially accounting for up to half of the unassigned mitochondrial proteins, or \(\sim 10\%\) of the total mitochondrial proteome. This raises the question of how expression of this class of genes is regulated and the nature of the mitochondrial–nuclear and mitochondrial–cytoplasmic communication pathways involved. The use of dATI permits antagonistic regulation, as translation of one isoform inherently opposes translation of the other isoform (61); therefore, deregulated ATI could result in category of human disease.

**SUPPLEMENTARY DATA**

Supplementary Data are available at NAR Online: Supplementary Tables 1–3 and Supplementary Figures 1–4.

**ACKNOWLEDGEMENTS**

We thank Professors A. Suomalainen, R. Wiesner and D. Blake for generous gifts of the TWINKLE, TFAM and TRIM32 antibodies, respectively.

**FUNDING**

Cambridge University Commonwealth Trust, Fellowship (to L.K.); UK Medical Research Council. Funding for open access charge: UK Medical Research Council.

**Conflict of interest statement.** None declared.

**REFERENCES**

1. Chaciniska,A., Koehler,C.M., Milenkovic,D., Lithgow,T. and Pfanner,N. (2009) Importing mitochondrial proteins: machineries and mechanisms. *Cell*, **138**, 628–644.
2. Wiedemann,N., Frazier,A.E. and Pfanner,N. (2004) The protein import machinery of mitochondria. *J. Biol. Chem.*, **279**, 14473–14476.
3. Bazzykin,G.A. and Kochetov,A.V. (2011) Alternative translation start sites are conserved in eukaryotic genomes. *Nucleic Acids Res.*, **39**, 567–577.
4. Prats,A.C., De Billy,G., Wang,P. and Darlix,J.L. (1989) CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. *J. Mol. Biol.*, **205**, 363–372.
5. Curran,J. and Kolokofsky,D. (1988) Ribosomal initiation from an ACG codon in the Sendai virus P/C mRNA. *EMBO J.*, **7**, 245–51.
6. Strubin,M., Long,E.O. and Mach,B. (1986) Two forms of the Ia antigen-associated invariant chain result from alternative initiations at two in-phase AUGs. *Cell*, **47**, 619–625.
7. Ivanov,I.P., Firth,A.E., Michel,A.M., Atkins,J.F. and Baranov,P.V. (2011) Identification of evolutionarily conserved non-AUG-initiated N-terminal extensions in human coding sequences. *Nucleic Acids Res.*, **39**, 4220–4234.
8. Suzuki,Y., Holmes,J.B., Cerritelli,S.M., Sakhuja,K., Minezuk,M., Holt,I.J. and Crouch,R.J. (2010) An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. *Mol. Cell. Biol.*, **30**, 5123–5134.
9. Leissring,M.A., Farris,W., Wu,X., Christodoulou,D.C., Haigis,M.C., Guarente,L. and Selkoe,D.J. (2004) Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. *Biochem. J.*, **383**, 439–446.
10. Land,T. and Rouault,T.A. (1998) Targeting of a human iron-sulfur cluster assembly enzyme, nis, to different subcellular compartments is regulated through alternative AUG utilization. *Mol. Cell.*, **2**, 807–815.
11. Wrutniak,C., Cassar-Malek,J., Marchal,S., Rasce,A., Heusser,S., Keller,J.M., Fléchon,J., Dauça,M., Samarut,J. and Ghyssael,J. (1995) A 43-kDa protein related to c-Erb A alpha 1 is located in the mitochondrial matrix of rat liver. J. Biol. Chem., 270, 16347–16354.

12. Petruzella,Y., Tirantti,V., Fernandez,P., Ianna,P., Carrozzo,R. and Zeviani,M. (1998) Identification and characterization of human cDNAs specific to BCS1, PET112, SCO1, COX15, and COX11, five genes involved in the formation and function of the mitochondrial respiratory chain. Genomics, 45, 494–504.

13. Cooper,H.M. and Spellbrink,J.N. (2008) The human SIRT3 protein deacetylase is exclusively mitochondrial. Biochem. J., 411, 279–285.

14. Reyes,A., He,J., Mao,C.C., Bailey,L.J., Di Re,M., Sembongi,H., Kazak,L., Dzionek,K., Holmes,J.B., Cluett,T.J. et al. (2011) Actin and myosin contribute to mammalian mitochondrial DNA maintenance. Nucleic Acids Res., 39, 5098–5108.

15. Flicek,P., Amode,M.R., Barrett,D., Beal,K., Brent,S., Carvalho-Silva,D., Clapham,P., Coates,G., Fairley,S., Fitzgerald,S. et al. (2012) Ensembl 2012. Nucleic Acids Res., 40, D84–D90.

16. Claros,M.G. and Vincens,P. (1996) Computational method to predict mitochondrially imported proteins and their targeting sequences. Eur. J. Biochem., 241, 779–786.

17. Emanuelsson,O., Bruns,N., von Heijne,G. and Nielsen,H. (2007) Locating proteins in the cell using TargetP, SignalP and related tools. Nat. Protoc., 2, 953–971.

18. Bannai,H., Tamada,Y., Maruyama,O., Nakai,K. and Miyano,S. (2002) Extensive feature detection of N-terminal protein sorting signals. Bioinformatics, 18, 298–305.

19. Pagliarini,D.J., Calvo,S.E., Chang,B., Vafai,S.B., Ong,S.-E., Walford,G.A., Sugiana,C., Boneh,A., Chen,W.K. et al. (2008) A mitochondrial protein compendium elucidates complex I disease biology. Cell, 134, 112–123.

20. Smith,A.C. and Robinson,A.J. (2009) MitoMiner, an integrated database for the storage and analysis of mitochondrial proteomics data. Mol. Cell. Proteomics, 8, 1324–1337.

21. Rorbach,J. and Minczuk,M. (2012) The post-transcriptional life of mammalian mitochondrial RNA. Biochem. J., 444, 357–373.

22. Kühn,U. and Wahle,E. (2004) Structure and function of poly(A) binding proteins. Biochim. Biophys. Acta, 1678, 67–84.

23. Wydro,M., Bobrowicz,A., Temperley,R.J., Lightowlers,R.N. and Zeviani,M. (1978) Reversible tenfold reduction in mitochondrial translation inhibition. Nucleic Acids Res., 38, 3732–3742.

24. He,J., Cooper,H.M., Reyes,A., Di Re,M., Sembongi,H., Litwin,T.R., Gao,J., Neuman,K.C., Fearnley,I.M., Spinazzola,A. et al. (2011) Crucial role for DNA ligase III in mitochondrial DNA content of human cells treated with ethidium bromide. Nucleic Acids Res., 39, 7750–7763.

25. Pinter,S.F., Auber,S.D. and Zeviani,V.A. (2008) The Schizosaccharomyces pombe Pif1p DNA helicase is essential for the maintenance of nuclear and mitochondrial DNA. Mol. Cell. Biol., 28, 6594–6608.

26. Zeh,J., Monson,E.K., Teng,S.C., Schulz,V.P. and Zeviani,V.A. (2000) Pif1p helicase, a catalytic inhibitor of telomerase in yeast. Science, 289, 771–774.

27. Patthy,M.K. and Zeviani,V.A. (2006) Human PIF helicase is cell cycle regulated and associates with telomerase. Cell Cycle, 5, 2796–2804.

28. Futami,K., Shimamoto,A. and Furuchi,Y. (2007) Mitochondrial nucleoid localization of human Pif1 helicase. Biochim. Biophys. Acta, 1768, 1685–1692.

29. Gagou,M.E., Goffart,S., Garstka,H.L., Montoya,J. and Ghysdael,J. (2012) Mitochondrial nucleoid interacting proteins support cell cycle regulated and associates with telomerase. Cell Cycle, 5, 2796–2804.

30. Small,I., Peeters,N., Legeai,F. and Lurin,C. (2004) Predator: a tool for rapidly screening proteomes for N-terminal targeting sequences. Proteomics, 4, 1581–1590.

31. Calvo,S., Jain,M., Xie,X., Sheth,S.A., Chang,B., Goldberger,O.A., Spinazzola,A., Zeviani,M., Carr,S.A. and Mootha,V.K. (2006) Systematic identification of human mitochondrial disease genes through integrative genomics. Nat. Genet., 38, 576–582.

32. Simsek,D., Fankhauser,C., Baker,A. and Schatz,G. (1989) The mitochondrial targeting signals of randomly generated peptide sequences correlates with predicted helical amphipathicity. J. Biol. Chem., 264, 20206–20215.

33. Leigh-Brown,S., Enriquez,J.A. and Odom,D.T. (2010) Nuclear transcription factors in mammalian mitochondria. Genome Biol., 11, 215.

34. Levertz,L.Y., Lee,B.-H., Min,X., Xu,B., Wедин,K., Earnest,S., Goldsmith,E.J. and Cobb,M.H. (2005) Properties of WNK1 and implications for other family members. J. Biol. Chem., 280, 26653–26658.

35. Chen,W., Chen,Y., Xu,B., Jiang,Y.-C., Stippec,S., Zhao,Y. and Cobb,M.H. (2009) Regulation of a third conserved phosphorylation site in SK1. J. Biol. Chem., 284, 3453–3460.

36. Kamal,J., McNeil,J.M., Fearnley,I.M. and Spinazzola,A. (2011) Functional and structural characterization of the mitochondrial targeting sequence of human PABPC1 and PABPC2. J. Biol. Chem., 286, 11609–11612.

37. Nakagawa,J., Maruyama,O., Nakai,K. and Miyano,S. (2002) Extensive feature detection of N-terminal protein sorting signals. Bioinformatics, 18, 298–305.

38. Kühn,U. and Wahle,E. (2004) Structure and function of poly(A) binding proteins. Biochim. Biophys. Acta, 1678, 67–84.

39. Wydro,M., Bobrowicz,A., Temperley,R.J., Lightowlers,R.N. and Zeviani,M. (1978) Reversible tenfold reduction in mitochondrial translation inhibition. Nucleic Acids Res., 38, 3732–3742.

40. He,J., Cooper,H.M., Reyes,A., Di Re,M., Sembongi,H., Litwin,T.R., Gao,J., Neuman,K.C., Fearnley,I.M., Spinazzola,A. et al. (2012) Mitochondrial nucleoid interacting proteins support mitochondrial protein synthesis. Nucleic Acids Res., 40, 6109–6121.

41. Poulton,J., Morten,K., Freeman-Emmerson,C., Potter,C., Sewry,C., Dubowitz,Y., Kidd,H., Stephenson,J., Whitehouse,W. and Hansen,F.J. (1994) Deficiency of the human mitochondrial transcription factor h-mtTFA in infantile mitochondrial myopathy is associated with mtDNA depletion. Hum. Mol. Genet., 3, 1763–1769.

42. Maniura-Weber,K., Goffart,S., Garstka,H.L., Montoya,J. and Wiesner,R.J. (2004) Transient overexpression of mitochondrial transcription factor A (TFAM) is sufficient to stimulate mitochondrial DNA transcription, but not sufficient to increase mtDNA copy number in cultured cells. Nucleic Acids Res., 32, 6015–6027.

43. Wiseman,A. and Attardi,G. (1978) Reversible tenfold reduction in mitochondria DNA content of human cells treated with ethidium bromide. Mol. Gen. Genet., 167, 51–63.

44. Rorbach,J., Nicholls,T.J.J. and Minczuk,M. (2011) PDE12 removes mitochondrial RNA poly(A) tails and controls translation in human mitochondria. Nucleic Acids Res., 39, 13673–13686.

45. Preiss,T., Chrzanowska-Lightowlers,Z.M. and Lightowlers,R.N. (1997) Glutamate dehydrogenase: an organelle-specific mRNA-binding protein. Trends Biochem. Sci., 22, 290.

46. Hoshoda,N., Lejeune,F. and Maquat,L.E. (2006) Evidence that poly(A) binding protein C1 binds nuclear pre-mRNA poly(A) tails. Mol. Cell. Biol., 26, 3085–3097.

47. Kimura,M., Ishida,K., Kashiban,S. and Baba,T. (2009) Characterization of two cytoplasmic poly(A)-binding proteins, PABPC1 and PABPC2, in mouse spermatogenic cells. Biol. Reprod., 80, 545–554.

48. Sladic,R.T., Lagnado,C.A., Bagley,C.J. and Goodall,G.J. (2004) Human PABP binds AU-rich RNA via RNA-binding domains 3 and 4. Eur. J. Biochem., 271, 450–457.

49. Niefeld,W., Mentzel,H. and Pieler,T. (1990) The Xenopus laevis poly(A) binding protein is composed of multiple functionally independent RNA binding domains. EMBO J., 9, 3699–3705.

50. Gray,N.K., Coller,J.M., Dickson,K.S. and Wickens,M. (2000) Multiple portions of poly(A)-binding protein stimulate translation in vitro. EMBO J., 19, 4723–4733.
51. Sachs, A.B., Davis, R.W. and Kornberg, R.D. (1987) A single domain of yeast poly(A)-binding protein is necessary and sufficient for RNA binding and cell viability. *Mol. Cell. Biol.*, 7, 3268–3276.

52. Kühn, U. and Pieler, T. (1996) Xenopus poly(A) binding protein: functional domains in RNA binding and protein-protein interaction. *J. Mol. Biol.*, 256, 20–30.

53. Brown, T.A., Tkachuk, A.N. and Clayton, D.A. (2008) Native R-loops persist throughout the mouse mitochondrial DNA genome. *J. Biol. Chem.*, 283, 36743–36751.

54. Szczesny, R.J., Borowski, L.S., Brzezniak, L.K., Dmochowska, A., Gewartowski, K., Bartnik, E. and Stepien, P.P. (2010) Human mitochondrial RNA turnover caught in flagranti: involvement of hSuv3p helicase in RNA surveillance. *Nucleic Acids Res.*, 38, 279–298.

55. Blanco, P., Sargent, C.A., Boucher, C.A., Howell, G., Ross, M. and Affara, N.A. (2001) A novel poly(A)-binding protein gene (PABPC5) maps to an X-specific subinterval in the Xq21.3/Yp11.2 homology block of the human sex chromosomes. *Genomics*, 74, 1–11.

56. Bochman, M.L., Sabouri, N. and Zakian, V.A. (2010) Unwinding the functions of the Pif1 family helicases. *DNA Repair*, 9, 237–249.

57. Huang, Y., Zhang, D.-H. and Zhou, J.-Q. (2006) Characterization of ATPase activity of recombinant human Pif1. *Acta Biochim. Biophys. Sin.*, 38, 335–341.

58. Kalifa, L., Beutner, G., Phadnis, N., Sheu, S. and Sia, E. (2009) Evidence for a role of FEN1 in maintaining mitochondrial DNA integrity. *DNA Repair*, 8, 1242–1249.

59. Lakshmipathy, U. and Campbell, C. (1999) The human DNA ligase III gene encodes nuclear and mitochondrial proteins. *Mol. Cell. Biol.*, 19, 3869–3876.

60. Zheng, L., Zhou, M., Guo, Z., Lu, H., Qian, L., Dai, H., Qiu, J., Yakubovskaya, E., Bogenhagen, D.F., Demple, B. et al. (2008) Human DNA2 is a mitochondrial nuclease/helicase for efficient processing of DNA replication and repair intermediates. *Mol. Cell.*, 32, 325–336.

61. Mueller, J.C., Andreoli, C., Prokisch, H. and Meitinger, T. (2004) Mechanisms for multiple intracellular localization of human mitochondrial proteins. *Mitochondrion*, 3, 315–325.